Welcome to our dedicated page for Hepion Pharmaceuticals news (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals reports developments around its transition into precision diagnostics, with a focus on blood-based tests for hepatocellular carcinoma and other disease areas. Company updates include the ctRNA biomarker assay licensed for early diagnosis and surveillance of HCC, the mSEPT9 PCR-based assay for liver cancer detection, and diagnostic test categories covering celiac disease, respiratory multiplex testing, H. pylori, and HCC.
Hepion news also covers public-company status changes and capital actions, including OTCQB trading, reverse stock split activity, Nasdaq delisting developments, leadership changes, stockholder voting matters, and the completed sale of rencofilstat-related patent assets, knowhow, clinical trial data, and drug product.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced its participation in the Benzinga Biotech Small Cap Conference on March 25, 2021. CEO Dr. Robert Foster will provide a corporate overview at 9:45 a.m. Eastern Time, while Dr. Patrick Mayo will join a panel discussion on NASH treatments at 1:00 p.m. Eastern Time. The company's lead drug candidate, CRV431, targets non-alcoholic steatohepatitis (NASH) and demonstrates potential in reducing liver fibrosis and tumor burden in experimental models. Hepion also leverages its AI-POWR™ platform to optimize patient treatment outcomes.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced its participation in the NASH-TAG 2021 Conference, taking place virtually from March 11-13, 2021. CEO Dr. Robert Foster will deliver an oral presentation on the positive top-line data from the Phase 2a ‘AMBITION’ clinical trial of CRV431, an innovative cyclophilin inhibitor. The presentation will highlight how the AI-POWR™ platform is utilized in optimizing study design for the upcoming Phase 2b trial. The presentation is scheduled for March 13, 2021, from 7:15 to 7:30 p.m. MT. More details can be found on the company's website.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced the closing of a public offering of 44,200,000 shares at $2.00 each, raising $88.4 million in gross proceeds. After expenses, the net proceeds amount to approximately $82.1 million. The funds will primarily support research and development activities along with general corporate needs. The offering was managed by ThinkEquity. Hepion's lead drug candidate, CRV431, targets liver diseases, particularly NASH, and shows promise for broader therapeutic applications.
Hepion Pharmaceuticals announced a public offering of 44,200,000 shares of common stock at $2.00 per share, raising gross proceeds of $88.4 million. The offering, managed by ThinkEquity, is set to close on February 18, 2021. The funds will support research and development activities, along with working capital. Hepion's lead drug candidate, CRV431, targets liver diseases, particularly non-alcoholic steatohepatitis (NASH). The company utilizes its AI platform, AI-POWR™, to enhance drug development and patient response identification.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced a proposed public offering of common stock, with all shares being sold by the Company. The offering is managed by ThinkEquity and is subject to market conditions. Proceeds will primarily be directed towards research and development, product development, and general corporate purposes. The securities are offered under a shelf registration statement previously filed with the SEC. The Company’s lead drug candidate, CRV431, targets liver disease.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced the appointment of Dr. Todd M. Hobbs as Chief Medical Officer, effective February 16, 2021. Dr. Hobbs, previously with Novo Nordisk for 16 years, will enhance Hepion's engagement with the FDA and key healthcare stakeholders. He is expected to play a significant role in advancing the clinical development of Hepion's lead drug candidate, CRV431, which targets non-alcoholic steatohepatitis (NASH) and liver disease. Hepion is utilizing its proprietary AI platform, AI-POWR™, to optimize treatment strategies for NASH patients.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced its participation in the BIO CEO & Investor Digital Conference from February 16 to 18, 2021. Their pre-recorded presentation will be available on demand for registered attendees and will also be accessible on their website for 30 days post-event. The company is focused on developing CRV431, a drug candidate targeting non-alcoholic steatohepatitis (NASH) and liver disease. Hepion is utilizing its proprietary AI platform, AI-POWR, to enhance drug development and identify optimal patient responses.
Hepion Pharmaceuticals (NASDAQ:HEPA), a clinical stage biopharmaceutical firm, announced its participation in two virtual investor conferences this January. The H.C. Wainwright BioConnect 2021 Conference will feature a pre-recorded presentation available on Hepion's website from January 11, 2021, for 90 days. Additionally, the Biotech Showcase 2021 Digital will provide on-demand content for registered participants. Hepion’s lead candidate, CRV431, targets non-alcoholic steatohepatitis (NASH) and is developed using their proprietary AI-POWR™ platform to enhance treatment outcomes.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced positive top-line results from the low-dose cohort of its Phase 2a 'AMBITION' clinical trial for CRV431, aimed at treating non-alcoholic steatohepatitis (NASH). The trial showed CRV431 to be generally safe and well tolerated, with significant reductions in key liver biomarkers, ALT and AST, observed over 28 days. The study continues with a higher dosage of 225 mg, with the completion of dosing expected in Q1 2021. The company will further analyze data to enhance the design of its Phase 2b trial, anticipated to start mid-2021.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced that the independent Data Safety Monitoring Board (DSMB) has confirmed the safety and tolerability of CRV431 in its Phase 2a AMBITION trial for NASH patients. The DSMB approved the continuation of the trial after two interim analyses and recommended moving to the final dosing cohort of 225 mg, expected to be completed in early 2021. The AMBITION trial, the first placebo-controlled study for CRV431, targets patients with moderate-to-severe fibrosis, aiming to demonstrate the drug's efficacy in reducing liver fibrosis.